Vanguard Group Inc Neurocrine Biosciences Inc Transaction History
Vanguard Group Inc
- $5.46 Trillion
- Q3 2024
A detailed history of Vanguard Group Inc transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Vanguard Group Inc holds 9,996,960 shares of NBIX stock, worth $1.26 Billion. This represents 0.02% of its overall portfolio holdings.
Number of Shares
9,996,960
Previous 10,056,446
0.59%
Holding current value
$1.26 Billion
Previous $1.38 Billion
16.87%
% of portfolio
0.02%
Previous 0.03%
Shares
14 transactions
Others Institutions Holding NBIX
# of Institutions
625Shares Held
94.2MCall Options Held
632KPut Options Held
621K-
Black Rock Inc. New York, NY14.2MShares$1.78 Billion0.04% of portfolio
-
State Street Corp Boston, MA5.15MShares$647 Million0.02% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny2.57MShares$323 Million0.47% of portfolio
-
Bellevue Group Ag Kuesnacht, V81.86MShares$234 Million3.62% of portfolio
-
Geode Capital Management, LLC Boston, MA1.86MShares$234 Million0.02% of portfolio
About NEUROCRINE BIOSCIENCES INC
- Ticker NBIX
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 95,639,296
- Market Cap $12B
- Description
- Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...